Form 4: Vertex Pharmaceuticals SVP Kristen Ambrose Reports Stock Transactions

Kristen Ambrose, SVP & Chief Accounting Officer of Vertex Pharmaceuticals, reports the disposition of common stock on February 10th and 11th, 2025.

Summary

• Kristen Ambrose, SVP & Chief Accounting Officer of Vertex Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On February 10, 2025, 591 shares of common stock were disposed of at a price of $467.98.
• On February 11, 2025, 1,376 shares of common stock were sold at a price of $459.83.
• Following these transactions, Ms. Ambrose beneficially owns 9,953 shares of Vertex Pharmaceuticals common stock.
• The transactions were made pursuant to a company-approved trading plan under Rule 10b5-1, which was entered into on August 8, 2024.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions by a company insider. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

Form 4 filings are a routine part of the US stock market and are required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors seeking to understand management's perspective on the company's stock.

Stakeholder Impact

• The stock sales by a company insider could be perceived negatively by some shareholders, although the existence of a pre-arranged trading plan mitigates this concern.

Key Dates